Zeynep Eroglu

Zeynep Eroglu

Hematology | Oncology
12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 123 publications

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Journal: JCO oncology practice
Published: June 23, 2026

iNOS is a key mediator of anti-PD-1 melanoma therapy response.

iNOS is a key mediator of anti-PD-1 melanoma therapy response.

Journal: Frontiers in immunology
Published: March 23, 2026

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.

Journal: Med (New York, N.Y.)
Published: March 17, 2026

Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.

Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.

Journal: Journal of neuro-oncology
Published: January 29, 2026

Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis.

Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis.

Journal: Cancers
Published: December 29, 2025

Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.

Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.

Journal: Journal for immunotherapy of cancer
Published: December 16, 2025

ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node Biopsy.

ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node Biopsy.

Journal: Annals of surgical oncology
Published: December 08, 2025

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Retraction Note: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Journal: Nature
Published: October 30, 2025

Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Journal: Frontiers in immunology
Published: October 03, 2025

Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During Treatment.

Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During Treatment.

Journal: Dermatology and therapy
Published: September 29, 2025

First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort.

First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort.

Journal: Cancer immunology, immunotherapy : CII
Published: September 15, 2025

Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients.

Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients.

Journal: Transplantation and cellular therapy
Published: September 04, 2025
Showing 1-12 of 123

Last Updated: 09/26/2026